CNBC's Jim Cramer explains why he is watching Gilead Sciences and Texas Instruments.
Some of the names on the move ahead of the open.
With biotechs in the political crosshairs, is now the time to look at the space? With Michael Yee, RBC Capital biotech analyst.
Among their favorites is Tesla, which has a $200 plus market price, according to a TD Ameritrade study.
Jim Cramer noted a change in leadership for stocks on Monday, and spelled out to investors how big money will play a rate hike.
Jim Cramer warned investors to keep their powder dry on this stock, before a tweeting politician has a field day on it.
Biotech stocks have underperformed the market but that could change as investors bet more deals could be in the making.
Pfizer buys Medivation for $14 billion in cash. CNBC's Meg Tirrell reports the latest.
Pfizer is in advanced talks to acquire Medivation for close to $14 billion, as it seeks to boost its oncology portfolio.
If investors are prepared to take some risks, these names could soar 50 percent over the next year, experts say.
Medivation briefly popped Wednesday after reports that at least five pharmaceutical companies expressed interest in buying it.
David Sowerby, Loomis Sayles & Co. vice president, and Steven Dudash, IHT Wealth Management president, share stocks they think can soar 50 percent or more over the next year.
Just buying the biggest share repurchasers doesn't seem to be working anymore. Here's what investors might want to do instead.
Stock buybacks aren't juicing share prices the way they once did, so it pays to be selective, according to UBS.
CNBC's Meg Tirrell reports the latest details on Valeant and its potential criminal probe. The "Fast Money Halftime Report" traders and Yana Barton, Eaton Vance portfolio manager, add perspective.
Biotech stocks have seen a big bounce in the past few weeks, as the group hits its highest level since January. Talking biotech, with David Seaburg, Cowen, and Chad Morganlander, Stifel Nicolaus.
Biotech hits a 6-month high. The "Fast Money Halftime Report" traders discusses whether they think it's time to buy biotech.
Ronny Gal, Sanford C. Bernstein, discusses the potential of a takeover deal for Biogen.
The "Fast Money" traders said on Tuesday that mergers and acquisitions may help the biotechnology sector hit new highs.
The "Fast Money" traders discuss their views on Biogen.